Top

Current Diabetes Reports

Published in:

05-07-2022 | Anemia | Pediatric Type 2 and Monogenic Diabetes (O Pinhas-Hamiel , Section Editor)

Diabetes Out-of-the-Box: Diabetes Mellitus and Impairment in Hearing and Vision

Authors: Noah Gruber, Orit Pinhas-Hamiel

Published in: Current Diabetes Reports | Issue 9/2022

Abstract

Purposeof Review

This review aims to provide an update on the etiologies of diabetes that are due to genetic disorders and that co-occur with impaired hearing or vision and to compare them. The potential mechanisms, including novel treatments, will be detailed.

Recent Findings

Wolfram syndrome, Kearns–Sayre syndrome, thiamine-responsive megaloblastic anemia, and maternally inherited diabetes and deafness are genetic disorders characterized by diabetes, impaired hearing, and vision. They differ in mode of inheritance, age at presentation, and the involvement of other organs; they are often misdiagnosed as type 1 or type 2 diabetes.

Summary

Suspicion of a genetic diabetes syndrome should be raised when pancreatic autoantibodies are negative, other organs are involved, and family history includes diabetes. Correct diagnosis of the various syndromes is important for tailoring the most advanced treatment, preventing disease progression, and enabling proper genetic counseling.

Hattersley AT, Greeley SAW, Polak M, et al. ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018;19:47–63.PubMedCrossRef

D B, A VR, B G, et al. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S17–38.CrossRef

Shi D, Motamed M, Mejía-Benítez A, Li L, Lin E, Budhram D, Kaur Y, Meyre D Genetic syndromes with diabetes: a systematic review. Obes Rev. (2021) https://doi.org/10.1111/OBR.13303

Yang Y, Chan L. Monogenic diabetes: what it teaches us on the common forms of type 1 and type 2 diabetes. Endocr Rev. 2016;37:190–222.PubMedPubMedCentralCrossRef

• Pallotta MT, Tascini G, Crispoldi R, Orabona C, Mondanelli G, Grohmann U, Esposito S Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med. (2019) https://doi.org/10.1186/s12967-019-1993-1An excellent review of Wolfram syndrome, including the etiology, pathogenesis, and future therapeutic interventions.

Zhang H, Colclough K, Gloyn AL, Pollin TI Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. (2021) https://doi.org/10.1172/JCI142244

Bonnycastle LL, Chines PS, Hara T, et al. Autosomal dominant diabetes arising from a Wolfram syndrome 1 mutation. Diabetes. 2013;62:3943–50.PubMedPubMedCentralCrossRef

De Franco E, Flanagan SE, Yagi T, et al. Dominant ER stress-inducing WFS1 mutations underlie a genetic syndrome of neonatal/infancy-onset diabetes, congenital sensorineural deafness, and congenital cataracts. Diabetes. 2017;66:2044–53.PubMedPubMedCentralCrossRef

Delvecchio M, Iacoviello M, Pantaleo A, Resta N Clinical spectrum associated with Wolfram syndrome type 1 and type 2: a review on genotype-phenotype correlations. Int J Environ Res Public Health. (2021) https://doi.org/10.3390/IJERPH18094796

10.

El-Shanti H, Lidral AC, Jarrah N, Druhan L, Ajlouni K. Homozygosity mapping identifies an additional locus for Wolfram syndrome on chromosome 4q. Am J Hum Genet. 2000;66:1229–36.PubMedPubMedCentralCrossRef

11.

Rigoli L, Di Bella C. Wolfram syndrome 1 and Wolfram syndrome 2. Curr Opin Pediatr. 2012;24:512–7.PubMedCrossRef

12.

Amr S, Heisey C, Zhang M, Xia XJ, Shows KH, Ajlouni K, Pandya A, Satin LS, El-Shanti H, Shiang R. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet. 2007;81:673–83.PubMedPubMedCentralCrossRef

13.

Harding HP, Ron D Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. (2002) https://doi.org/10.2337/DIABETES.51.2007.S455

14.

Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001;7:1153–63.PubMedCrossRef

15.

Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120:744–55.PubMedPubMedCentralCrossRef

16.

Yamada T, Ishihara H, Tamura A, et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet. 2006;15:1600–9.PubMedCrossRef

17.

Chen YF, Kao CH, Chen YT, et al. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes Dev. 2009;23:1183–94.PubMedPubMedCentralCrossRef

18.

•• Abreu D, Urano F. Current landscape of treatments for Wolfram syndrome. Trends Pharmacol Sci. 2019;40:711–4. (This study emphasizes the treatment targeted at the endoplasmic reticulum stress pathogenesis of Wolfram syndrome.)PubMedPubMedCentralCrossRef

19.

Lombardo F, Salzano G, Di Bella C, Aversa T, Pugliatti F, Cara S, Valenzise M, De Luca F, Rigoli L. Phenotypical and genotypical expression of Wolfram syndrome in 12 patients from a Sicilian district where this syndrome might not be so infrequent as generally expected. J Endocrinol Invest. 2014;37:195–202.PubMedCrossRef

20.

Medlej R, Wasson J, Baz P, Azar S, Salti I, Loiselet J, Permutt A, Halaby G. Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab. 2004;89:1656–61.PubMedCrossRef

21.

Pallotta MT, Tascini G, Crispoldi R, Orabona C, Mondanelli G, Grohmann U, Esposito S. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med. 2019;17:238.PubMedPubMedCentralCrossRef

22.

Al-Till M, Jarrah NS, Ajlouni KM. Ophthalmologic findings in fifteen patients with Wolfram syndrome. Eur J Ophthalmol. 2002;12:84–8.PubMedCrossRef

23.

Rotsos T, Papakonstantinou E, Symeonidis C, Krassas A, Kamakari S. Wolfram syndrome: a case report of two sisters Wolfram syndrome: case report of two sisters. Am J Ophthalmol case reports. 2022;26:101452.CrossRef

24.

Soares A, Mota Á, Fonseca S, Faria O, Brandaõ E, Falcaõ Dos Reis F, Gentil R, Guimarães S, Mendonca L. Ophthalmologic manifestations of Wolfram syndrome: report of 14 cases. Ophthalmologica. 2019;241:116–9.PubMedCrossRef

25.

Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet (London, England). 1995;346:1458–63.CrossRef

26.

Kinsley BT, Swift M, Dumont RH, Swift RG. Morbidity and mortality in the Wolfram syndrome. Diabetes Care. 1995;18:1566–70.PubMedCrossRef

27.

Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83:921–9.PubMedCrossRef

28.

Kondo M, Tanabe K, Amo-Shiinoki K, Hatanaka M, Morii T, Takahashi H, Seino S, Yamada Y, Tanizawa Y. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome. Diabetologia. 2018;61:2189–201.PubMedCrossRef

29.

• Jagomäe T, Seppa K, Reimets R, et al Early intervention and lifelong treatment with GLP1 receptor agonist liraglutide in a Wolfram syndrome rat model with an emphasis on visual neurodegeneration, sensorineural hearing loss and diabetic phenotype. Cells. (2021) https://doi.org/10.3390/CELLS10113193An animal model study that shows promise to patients with Wolfram syndrome, in regard to the visual, hearing, and diabetes aspects of the disease.

30.

Seppa K, Toots M, Reimets R, et al GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome. Sci Rep. (2019) https://doi.org/10.1038/S41598-019-52295-2

31.

Kakiuchi C, Ishigaki S, Oslowski CM, Fonseca SG, Kato T, Urano F Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94. PLoS One. (2009) https://doi.org/10.1371/JOURNAL.PONE.0004134

32.

Lu S, Kanekura K, Hara T, et al. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proc Natl Acad Sci U S A. 2014;111:E5292–301.PubMedPubMedCentral

33.

Nguyen LD, Fischer TT, Abreu D, Arroyo A, Urano F, Ehrlich BE. Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome. Proc Natl Acad Sci U S A. 2020;117:17389–98.PubMedPubMedCentralCrossRef

34.

Washington University School of Medicine NI of H (NIH), (NIDDK) NI of D and D and KD A clinical trial of dantrolene sodium in pediatric and adult patients with Wolfram syndrome. https://clinicaltrials.gov/ct2/show/NCT02829268.

35.

Shang L, Hua H, Foo K, et al. β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes. 2014;63:923–33.PubMedPubMedCentralCrossRef

36.

Iafusco D, Zanfardino A, Piscopo A, et al. Metabolic treatment of Wolfram syndrome. Int J Environ Res Publ Health. 2022;19:2755.CrossRef

37.

Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325–32.PubMedPubMedCentral

38.

Björkman K, Vissing J, Østergaard E, et al Phenotypic spectrum and clinical course of single large-scale mitochondrial DNA deletion disease in the paediatric population: a multicentre study. J Med Genet jmedgenet-2021–108006 (2021)

39.

Broomfield A, Sweeney MG, Woodward CE, et al. Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease. J Inherit Metab Dis. 2015;38:445–57.PubMedCrossRef

40.

•• Sequiera GL, Srivastava A, Alagarsamy KN, Rockman-Greenberg C, Dhingra S Generation and evaluation of isogenic iPSC as a source of cell replacement therapies in patients with Kearns Sayre syndrome. Cells (2021) 10:1–15 This important study demonstrated for the first time that peripheral blood mononuclear cell-induced pluripotent stem cells that represented an isogenic source of patient-specific personalized cell replacement therapies in Kearns–Sayre syndrome.

41.

Sabella-Jiménez V, Otero-Herrera C, Silvera-Redondo C, Garavito-Galofre P Mitochondrial DNA deletion and duplication in Kearns-Sayre syndrome (KSS) with initial presentation as Pearson Marrow-Pancreas syndrome (PMPS): two case reports in Barranquilla, Colombia. Mol Genet genomic Med. (2020) https://doi.org/10.1002/MGG3.1509

42.

Bhatnagar K, Gupta D. Kearns Sayre syndrome. Med J Dr DY Patil Univ. 2022;7:252–5.CrossRef

43.

Yamashita S, Nishino I, Nonaka I, Goto YI. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J Hum Genet. 2008;53:598–606.PubMedCrossRef

44.

Epstein AE, Dimarco JP, Ellenbogen KA, et al ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. (2008) https://doi.org/10.1161/CIRCUALTIONAHA.108.189742

45.

Trivedi M, Goldstein A, Arora G. Prophylactic pacemaker placement at first signs of conduction disease in Kearns-Sayre syndrome. Cardiol Young. 2018;28:1487–8.PubMedCrossRef

46.

•• Jacoby E, Ben Yakir-Blumkin M, Blumenfeld-Kan S, et al. Mitochondrial augmentation of CD34 + cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit. NPJ Regen Med. 2021. https://doi.org/10.1038/S41536-021-00167-71093. (This revolutionary study supports mitochondria augmentation technology as a potential disease-modifying therapy for mtDNA disorders.)CrossRefPubMedPubMedCentral

47.

•• Zhang S, Qiao Y, Wang Z, Zhuang J, Sun Y, Shang X, Li G Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia. Clin Chim Acta (2021) 516:157–168 This review summarizes the genotypes and phenotypes of most of the families described in the literature with thiamine-responsive megaloblastic anemia.

48.

• Jungtrakoon P, Shirakawa J, Buranasupkajorn P, et al. Loss-of-function mutation in thiamine transporter 1 in a family with autosomal dominant diabetes. Diabetes. 2019;68:1084–93. (A description of heterozygous carriers of the gene that causes thiamine-responsive megaloblastic anemia, which manifests as adult-onset diabetes.)PubMedPubMedCentralCrossRef

49.

Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, Ortigoza-Escobar JD, Pérez-Dueñas B. Genetic defects of thiamine transport and metabolism: a review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis. 2019;42:581–97.PubMedCrossRef

50.

Neufeld EJ, Mandel H, Raz T, Szargel R, Yandava CN, Stagg A, Fauré S, Barrett T, Buist N, Cohen N. Localization of the gene for thiamine-responsive megaloblastic anemia syndrome, on the long arm of chromosome 1, by homozygosity mapping. Am J Hum Genet. 1997;61:1335–41.PubMedPubMedCentralCrossRef

51.

Warncke K, Prinz N, Iotova V, et al. Thiamine-responsive megaloblastic anemia-related diabetes: long-term clinical outcomes in 23 pediatric patients from the DPV and SWEET registries. Can J diabetes. 2021;45:539–45.PubMedCrossRef

52.

Shaw-Smith C, Flanagan SE, Patch AM, et al. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. Pediatr Diabetes. 2012;13:314–21.PubMedCrossRef

53.

Sun C, Pei Z, Zhang M, Sun B, Yang L, Zhao Z, Cheng R, Luo F. Recovered insulin production after thiamine administration in permanent neonatal diabetes mellitus with a novel solute carrier family 19 member 2 (SLC19A2) mutation. J Diabetes. 2018;10:50–8.PubMedCrossRef

54.

Di Giaimo R, Riccio M, Santi S, Galeotti C, Ambrosetti DC, Melli M. Targeted disruption of Slc19a2, the gene encoding the high-affinity thiamin transporter Thtr-1, causes diabetes mellitus, sensorineural deafness and megaloblastosis in mice. Hum Mol Genet. 2002;11:2951–60.CrossRef

55.

• Yang M, Xu L, Xu C, Cui Y, Jiang S, Dong J, Liao L (2021) The mutations and clinical variability in maternally inherited diabetes and deafness: an analysis of 161 patients. Front Endocrinol (Lausanne). https://doi.org/10.3389/FENDO.2021.728043(This large summary of patients with maternally inherited diabetes and deafness emphasizes that young onset of diabetes with normal BMI, maternal inheritance, and impairments of multiple systems should prompt genetic testing)CrossRefPubMedCentral

56.

Robinson KN, Terrazas S, Giordano-Mooga S, Xavier NA. The role of heteroplasmy in the diagnosis and management of maternally inherited diabetes and deafness. Endocr Pract. 2020;26:241–6.PubMedCrossRef

57.

Ali AS, Ekinci EI, Pyrlis F. Maternally inherited diabetes and deafness (MIDD): an uncommon but important cause of diabetes. Endocr Metab Sci. 2021;2:5.CrossRef

58.

Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med. 2008;25:383–99.PubMedCrossRef

59.

Horikawa Y, Enya M Genetic dissection and clinical features of MODY6 (NEUROD1-MODY). Curr Diab Rep (2021) https://doi.org/10.1007/S11892-019-1130-9

60.

Melis D, Carvalho D, Barbaro-Dieber T, et al. Primrose syndrome: characterization of the phenotype in 42 patients. Clin Genet. 2020;97:890–901.PubMedPubMedCentralCrossRef

61.

• Montaser H, Patel KA, Balboa D, et al. Loss of MANF causes childhood-onset syndromic diabetes due to increased endoplasmic reticulum stress. Diabetes. 2021;70:1006–18. (The first report of two patients with MANF disease. The first patient was reported earlier in 2015.)PubMedPubMedCentralCrossRef

62.

Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Luis SJ, Broshtilova V, Zlotogorski A. H syndrome: the first 79 patients. J Am Acad Dermatol. 2014;70:80–8.PubMedCrossRef

Title: Diabetes Out-of-the-Box: Diabetes Mellitus and Impairment in Hearing and Vision
Authors: Noah Gruber
Orit Pinhas-Hamiel
Publication date: 05-07-2022
Publisher: Springer US
Keywords: Anemia
Diabetes
Published in: Current Diabetes Reports / Issue 9/2022
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-022-01483-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purposeof Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2022

Risk of Type 2 Diabetes Among Individuals with Excess Weight: Weight Trajectory Effects

Electronic Health Record–Based Decision-Making Support in Inpatient Diabetes Management

Pharmacist Role in Providing Inpatient Diabetes Management

CGM in the Hospital: Is It Ready for Prime Time?

Lipodystrophy for the Diabetologist—What to Look For

Content Validity of Patient-Reported Outcome Measures Developed for Assessing Health-Related Quality of Life in People with Type 2 Diabetes Mellitus: a Systematic Review

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage